Skip to main content
Edition No. 104 · GlobalEst. 2026
S&P 5007,340.53-2.40%Dow Jones50,759.42-2.82%Nasdaq24,328.38-2.94%FTSE 10010,689.87-0.57%DAX26,045.37-1.15%Nikkei 22558,860.43-3.22%Hang Seng23,508.17-4.27%EUR/USD1.0988-0.96%GBP/USD1.3199-0.59%Gold3,852.90-0.83%Crude Oil85.86-3.25%Bitcoin64,810.36+1.06%S&P 5007,340.53-2.40%Dow Jones50,759.42-2.82%Nasdaq24,328.38-2.94%FTSE 10010,689.87-0.57%DAX26,045.37-1.15%Nikkei 22558,860.43-3.22%Hang Seng23,508.17-4.27%EUR/USD1.0988-0.96%GBP/USD1.3199-0.59%Gold3,852.90-0.83%Crude Oil85.86-3.25%Bitcoin64,810.36+1.06%

New Blood Pressure Medication Shows Promise in Global Clinical Trial

The drug baxdrostat successfully lowered blood pressure in patients where traditional treatments had previously failed.

By Planet Earth News Health & Fitness Desk· Published 2026-10-23· 2 min read
Towfiqu barbhuiya / Pexels / Pexels
PENN Explainer

Hear this story explained in 90 seconds.

A major international clinical trial has revealed a new medication that could change how doctors treat high blood pressure. The study, known as the BaxHTN trial, focused on a drug called baxdrostat that is taken as a daily tablet. Researchers presented the findings at the European Society of Cardiology Congress 2025 in Madrid. The results were simultaneously published in the New England Journal of Medicine. This development offers a potential new path for patients who do not respond to standard therapies. Nearly 800 patients across 214 clinics worldwide participated in the research. Professor Bryan Williams, who led the trial at the University College London Institute of Cardiovascular Science, oversaw the assessment of the drug. The study was sponsored by the pharmaceutical company AstraZeneca. After 12 weeks of treatment, patients taking the medication showed significant improvements in their blood pressure levels. The trial was supported by the National Institute for Health and Care Research Biomedical Research Centre at University College London Hospitals. High blood pressure remains a leading global health challenge that contributes to heart disease and stroke. Many patients currently struggle to manage their condition despite using existing medications. The success of this trial suggests that targeting specific biological pathways can provide relief for those with resistant hypertension. Researchers are now looking at the long-term implications of this treatment for global public health. Future steps will likely involve further monitoring of patient outcomes to ensure the drug remains safe and effective over extended periods. This study highlights the ongoing importance of international collaboration in medical research to address chronic health conditions.

You've reached your free article limit

You've read 10 of 10 free articles this month. Subscribe to Planet Earth News Network for unlimited access to neutral, global journalism — plus puzzles, podcasts, and the weekly newsletter.

Already a subscriber? Sign in.

Ask the Author

Subscribers can ask the journalist a question about this story. Subscribe to ask.

Neutrality note

Auto-harvested from global news wires and presented neutrally by PENN.

Share this article

to vote

Comments

No comments yet — be the first to share your thoughts.

Related stories in Health and Fitness